General characteristics of patients who underwent transplantation
| . | Total (n = 92) . | Survival group (n = 48) . | Death group (n = 44) . | P value . |
|---|---|---|---|---|
| Age, y | 25 (18-58) | 23.5 (18-58) | 28 (18-56) | .086 |
| Sex, M/F | 61/31 | 32/16 | 29/15 | .939 |
| Relapse, Y/N | 25/67 | 11/37 | 14/30 | .338 |
| Refractory, Y/N | 16/76 | 5/43 | 11/33 | .065 |
| DSI, Y/N | 26/66 | 6/42 | 20/24 | <.001∗∗ |
| DLI, Y/N | 17/75 | 7/41 | 10/34 | .315 |
| aGVHD grade | .241 | |||
| Non | 15 (16.3%) | 11 (22.9%) | 4 (9.1%) | |
| 1 | 19 (20.7%) | 12 (25%) | 7 (15.9%) | |
| 2 | 45 (48.9%) | 21 (43.8%) | 24 (54.5%) | |
| 3 | 10 (10.9%) | 4 (8.3%) | 6 (13.6%) | |
| 4 | 3 (3.3%) | 0 (0%) | 3 (6.8%) | |
| cGVHD, Y/N | 36/56 | 24/24 | 12/32 | .026∗ |
| Hepatomegaly, Y/N | 39/53 | 21/27 | 18/26 | .783 |
| Splenomegaly, Y/N | 82/10 | 40/8 | 42/2 | .126 |
| BM hemophagocytosis, Y/N | 68/24 | 36/12 | 32/12 | .804 |
| Coagulation abnormalities, Y/N | 35/34 | 16/24 | 19/10 | .036∗ |
| Time from diagnosis to HSCT, d | 83 (26-1 035) | 86.5 (26-558) | 81.5 (37-1 035) | .560 |
| ANC, ×109/L | 1.5 (0.03-10.34) | 1.5 (0.03-6.47) | 1.59 (0.27-10.34) | .969 |
| Hb, g/L | 99 ± 25 | 100 ± 26 | 99 ± 24 | .824 |
| PLT, ×109/L | 88 (11-454) | 89.5 (16-396) | 81 (11-454) | .839 |
| ALT, U/L | 79.5 (11-861) | 79.5 (11-672) | 80 (11-861) | .566 |
| ALB, g/L | 31.3 ± 5.2 | 31.6 ± 4.6 | 31.0 ± 5.8 | .566 |
| Cr, μmol/L | 47.5 (23.9-226.8) | 44.75 (23.9-226.8) | 53.1 (25.4-217.4) | .003∗ |
| BUN, mmol/L | 4.63 (1.26-29.16) | 4.25 (1.26-23.01) | 4.76 (1.63-29.16) | .477 |
| TG, mmol/L | 2.08 (0.66-9.18) | 2.62 (0.66-5.29) | 1.87 (0.76-9.18) | .023∗ |
| FIB, g/L | 1.64 (0.39-4.7) | 1.63 (0.39-4.7) | 1.64 (0.55-3.84) | .876 |
| FER, μg/L | 1 483.7 (61.5-75 000) | 1 424.1 (61.5-73 320) | 1 719.95 (119.9-75 000) | .950 |
| β2M, mg/L | 4.05 (1.36-22.4) | 3.18 (1.36-12.4) | 4.75 (1.38-22.4) | .068 |
| sCD25, pg/mL | 21 384 (222-155 915) | 16 551 (222-71 125) | 25 968 (842-155 915) | .015∗ |
| NK-cell activity, % | 15.05 (6.97-41.66) | 15.05 (6.97-24.5) | 15.04 (7.63-41.66) | .799 |
| EBER (+/–) | 60/27 | 31/15 | 29/12 | .737 |
| Plasma EBV copies/mL at diagnosis | 9 150 (0-7 600 000) | 6 000 (0-5 300 000) | 19 500 (0-7 600 000) | .027∗ |
| PBMC EBV copies/mL at diagnosis | 52 000 (0-32 300 000) | 58 000 (0-23 000 000) | 50 000 (0-32 300 000) | .574 |
| Plasma EBV copies/mL before HSCT | 0 (0-270 000) | 0 (0-26 000) | 670 (0-270 000) | .032∗ |
| PBMC EBV copies/mL before HSCT | 4 900 (0-9 000 000) | 4 450 (0-9 000 000) | 5 100 (0-4 700 000) | .997 |
| Plasma EBV copies/mL after HSCT | 0 (0-20 000) | 0 (0-4 200) | 0 (0-20 000) | .047∗ |
| PBMC EBV copies/mL after HSCT | 775 (0-180 000) | 685 (0-180 000) | 900 (0-170 000) | .618 |
| IL-2, pg/mL | 2 (1-8.2) | 2 (1-8.2) | 1 (1-2) | .003∗ |
| IL-6, pg/mL | 5.5 (0-201.8) | 5.52 (0-201.8) | 5.31 (0-61.6) | .440 |
| IL-10, pg/mL | 2.8 (0.4-1 354) | 1.8 (0.4-378.1) | 8.7 (0.4-1 354) | .035∗ |
| IL-1RA, pg/mL | 195.5 (0-26 669) | 185.65 (7.3-12 813) | 740.8 (0-26 669) | .051 |
| IFN-γ, pg/mL | 65.4 (0-953.05) | 40.3 (0-761.53) | 85.4 (0-953.05) | .423 |
| TNF-α, pg/mL | 5.85 (2.16-78.15) | 5.72 (2.16-78.15) | 6 (2.5-45.09) | .506 |
| IL-18, pg/mL | 124.8 (5.11-1 136) | 98.8 (5.11-1 136) | 146.2 (7.3-1 110) | .165 |
| . | Total (n = 92) . | Survival group (n = 48) . | Death group (n = 44) . | P value . |
|---|---|---|---|---|
| Age, y | 25 (18-58) | 23.5 (18-58) | 28 (18-56) | .086 |
| Sex, M/F | 61/31 | 32/16 | 29/15 | .939 |
| Relapse, Y/N | 25/67 | 11/37 | 14/30 | .338 |
| Refractory, Y/N | 16/76 | 5/43 | 11/33 | .065 |
| DSI, Y/N | 26/66 | 6/42 | 20/24 | <.001∗∗ |
| DLI, Y/N | 17/75 | 7/41 | 10/34 | .315 |
| aGVHD grade | .241 | |||
| Non | 15 (16.3%) | 11 (22.9%) | 4 (9.1%) | |
| 1 | 19 (20.7%) | 12 (25%) | 7 (15.9%) | |
| 2 | 45 (48.9%) | 21 (43.8%) | 24 (54.5%) | |
| 3 | 10 (10.9%) | 4 (8.3%) | 6 (13.6%) | |
| 4 | 3 (3.3%) | 0 (0%) | 3 (6.8%) | |
| cGVHD, Y/N | 36/56 | 24/24 | 12/32 | .026∗ |
| Hepatomegaly, Y/N | 39/53 | 21/27 | 18/26 | .783 |
| Splenomegaly, Y/N | 82/10 | 40/8 | 42/2 | .126 |
| BM hemophagocytosis, Y/N | 68/24 | 36/12 | 32/12 | .804 |
| Coagulation abnormalities, Y/N | 35/34 | 16/24 | 19/10 | .036∗ |
| Time from diagnosis to HSCT, d | 83 (26-1 035) | 86.5 (26-558) | 81.5 (37-1 035) | .560 |
| ANC, ×109/L | 1.5 (0.03-10.34) | 1.5 (0.03-6.47) | 1.59 (0.27-10.34) | .969 |
| Hb, g/L | 99 ± 25 | 100 ± 26 | 99 ± 24 | .824 |
| PLT, ×109/L | 88 (11-454) | 89.5 (16-396) | 81 (11-454) | .839 |
| ALT, U/L | 79.5 (11-861) | 79.5 (11-672) | 80 (11-861) | .566 |
| ALB, g/L | 31.3 ± 5.2 | 31.6 ± 4.6 | 31.0 ± 5.8 | .566 |
| Cr, μmol/L | 47.5 (23.9-226.8) | 44.75 (23.9-226.8) | 53.1 (25.4-217.4) | .003∗ |
| BUN, mmol/L | 4.63 (1.26-29.16) | 4.25 (1.26-23.01) | 4.76 (1.63-29.16) | .477 |
| TG, mmol/L | 2.08 (0.66-9.18) | 2.62 (0.66-5.29) | 1.87 (0.76-9.18) | .023∗ |
| FIB, g/L | 1.64 (0.39-4.7) | 1.63 (0.39-4.7) | 1.64 (0.55-3.84) | .876 |
| FER, μg/L | 1 483.7 (61.5-75 000) | 1 424.1 (61.5-73 320) | 1 719.95 (119.9-75 000) | .950 |
| β2M, mg/L | 4.05 (1.36-22.4) | 3.18 (1.36-12.4) | 4.75 (1.38-22.4) | .068 |
| sCD25, pg/mL | 21 384 (222-155 915) | 16 551 (222-71 125) | 25 968 (842-155 915) | .015∗ |
| NK-cell activity, % | 15.05 (6.97-41.66) | 15.05 (6.97-24.5) | 15.04 (7.63-41.66) | .799 |
| EBER (+/–) | 60/27 | 31/15 | 29/12 | .737 |
| Plasma EBV copies/mL at diagnosis | 9 150 (0-7 600 000) | 6 000 (0-5 300 000) | 19 500 (0-7 600 000) | .027∗ |
| PBMC EBV copies/mL at diagnosis | 52 000 (0-32 300 000) | 58 000 (0-23 000 000) | 50 000 (0-32 300 000) | .574 |
| Plasma EBV copies/mL before HSCT | 0 (0-270 000) | 0 (0-26 000) | 670 (0-270 000) | .032∗ |
| PBMC EBV copies/mL before HSCT | 4 900 (0-9 000 000) | 4 450 (0-9 000 000) | 5 100 (0-4 700 000) | .997 |
| Plasma EBV copies/mL after HSCT | 0 (0-20 000) | 0 (0-4 200) | 0 (0-20 000) | .047∗ |
| PBMC EBV copies/mL after HSCT | 775 (0-180 000) | 685 (0-180 000) | 900 (0-170 000) | .618 |
| IL-2, pg/mL | 2 (1-8.2) | 2 (1-8.2) | 1 (1-2) | .003∗ |
| IL-6, pg/mL | 5.5 (0-201.8) | 5.52 (0-201.8) | 5.31 (0-61.6) | .440 |
| IL-10, pg/mL | 2.8 (0.4-1 354) | 1.8 (0.4-378.1) | 8.7 (0.4-1 354) | .035∗ |
| IL-1RA, pg/mL | 195.5 (0-26 669) | 185.65 (7.3-12 813) | 740.8 (0-26 669) | .051 |
| IFN-γ, pg/mL | 65.4 (0-953.05) | 40.3 (0-761.53) | 85.4 (0-953.05) | .423 |
| TNF-α, pg/mL | 5.85 (2.16-78.15) | 5.72 (2.16-78.15) | 6 (2.5-45.09) | .506 |
| IL-18, pg/mL | 124.8 (5.11-1 136) | 98.8 (5.11-1 136) | 146.2 (7.3-1 110) | .165 |
Coagulation abnormalities are indicated by prolonged PT and/or APTT. ∗P < .05; ∗∗P < .001.